Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02243163
Other study ID # 1020106
Secondary ID
Status Recruiting
Phase N/A
First received September 16, 2014
Last updated September 16, 2014
Start date May 2014
Est. completion date April 2015

Study information

Verified date September 2014
Source Chang Bing Show Chwan Memorial Hospital
Contact Shin-Mae Wang, MD.
Email wangznmg@gmail.com
Is FDA regulated No
Health authority Taiwan: Ministry of Health and Welfare
Study type Interventional

Clinical Trial Summary

The purpose of study is to investigate if yoga exercise improve life quality and immune status in breast cancer patients after complete treatment (including surgery and / or radiotherapy and / or chemotherapy)


Description:

It is well-known that exercise promote immune regulation for better life quality. However, the mechanism for better immunity and life quality is not clear. We postulate that Ayurveda yoga might benefit breast cancer women with completion of operation and/or chemotherapy and radiotherapy. The benefits could be due to immune modulation, and improve health perception and life quality, and even potential decrease of cancer relapse.

The study patients will do yoga twice a week for 12 weeks. The study primary endpoints are 1) to improve personal health perception, 2) to improve life quality and 3) to enhance human immunity. The study secondary endpoint will follow up the immunity changes 3 months after the intervention.

We anticipate to reach the primary endpoints and to publish the primary results in one year, the secondary endpoint will complete in the second year.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date April 2015
Est. primary completion date April 2015
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 65 Years
Eligibility Inclusion Criteria:

- Able to attend yoga program weekly, and fill out inform consent.

- Patients with breast cancer after complete treatment for at least 3 months (including surgery and / or radiotherapy and/or chemotherapy).

Exclusion Criteria:

- male

- overweight

- unable to do yoga exercise.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Behavioral:
Yoga exercise
Subjects will receive regular 90-minutes yoga classes twice a week for 3 months.

Locations

Country Name City State
Taiwan Division of Core Laboratory; Chang Bing Show Chwan Memorial Hospital Changhua County

Sponsors (1)

Lead Sponsor Collaborator
Chang Bing Show Chwan Memorial Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Improve personal health and life quality Health and life quality will assessed by modified fatigue inventory and EORTC QLQ-C30 (version 3) at three different times: (1)baseline data: before yoga exercise, (2)outcome data: at 6 and 12 weeks post-test. Change from baseline in personal health and life quality at 6 months. No
Secondary Immune modulation Lymphocytes will be extracted from peripheral blood for analyses of lymphocytes subpopulation (Th1/ Th2/ Treg/ Th17), polarization (T-bet/ Gata-3/ Foxp3/ RORrt) and its related cytokines (Th1: IL-12/ IFN-?/ IL-27; Th2: IL-4/ IL-13/ IL-25; Th17: IL-17A/ IL-6/ IL-21; Treg: TGF/ IL-10. Saliva collection for analyses of cortisol and IL-6 at 3 different times: (1) baseline data: before yoga exercise, (2)outcome data: at 6 and 12 weeks post-test. Change from baseline in human immunity at 3 months. No
See also
  Status Clinical Trial Phase
Completed NCT04290585 - Technology and Health Communication in Improving Health Outcomes in Patients Scheduled for Mammography N/A
Terminated NCT02540330 - A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant Phase 2
Completed NCT02005770 - Anesthesia and Circulating Tumor Cells in Breast Cancer Phase 4
Completed NCT01643148 - The Tetrad BMI, Leptin, Leptin/Adiponectin (L/A) Ratio and CA-15-3 is a Reliable Biomarker of Breast Cancer N/A
Active, not recruiting NCT02942355 - Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer Phase 2